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ORIGINAL RESEARCH

Antibiotic-Mediated Inhibition of Porcine Reproductive
and Respiratory Syndrome Virus (PRRSV) Infection: A Novel
Quinolone Function Which Potentiates the Antiviral Cytokine
Response in MARC-145 Cells and Pig Macrophages
William A. Cafruny 1, Richard G. Duman 1, Raymond R. Rowland 2, Eric A. Nelson 3,
and Grace H. Wong 4
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Abstract: Porcine reproductive and respiratory syndrome virus (PRRSV) is an economically significant agent for which
there currently are no effective treatments. Development of antiviral agents for PRRSV as well as many other viruses has
been limited by toxicity of known antiviral compounds. In contrast, antibiotics for non-virus microbial infections have been
widely useful, in part because of their acceptable toxicity in animals. We report here the discovery that the quinolonecontaining compound Plasmocin™, as well as the quinolones nalidixic acid and ciprofloxacin, have potent anti-PRRSV
activity in vitro. PRRSV replication was inhibited by these antibiotics in both cultured MARC-145 cells and cultured primary
alveolar porcine macrophages (PAMs). Furthermore, sub-optimal concentrations of nalidixic acid synergized with antiviral
cytokines (AK-2 or IFN-γ) to quantitatively and qualitatively inhibit PRRSV replication in MARC-145 cells or PAMs.
The antiviral activity of Plasmocin and nalidixic acid correlated with reduced actin expression in MARC-145 cells. Replication of the related lactate dehydrogenase-elevating virus (LDV) was also inhibited in primary mouse macrophages by
Plasmocin. These results are significant to the development of antiviral strategies with potentially reduced toxicity, and
provide a model system to better understand regulation of arterivirus replication.
Keywords: PRRSV, quinolones, IFN-γ, AK-2, virus inhibition

Introduction

Antimicrobial agents used to treat bacterial or fungal infections generally interfere with specific processes
that are essential for microbe growth and/or division, for example cell wall synthesis, cytoplasmic membrane
function, nucleic acid synthesis, or ribosome function (Neu and Gootz, 1996). On the other hand, antiviral
chemotherapy may target the cells supporting virus replication as well as events specific to the virus, with
potentially toxic side effects (De Clerq, 1996). Toxicity to the host is also well known for some antibiotics,
including hematologic suppression, kidney and liver injury due to metabolism in those organs, as well as
neurological side effects (Snavely and Hodges, 1984; Neu and Gootz, 1996; Chow et al. 2004), demonstrating the potential for direct host effects of antibiotics. The mechanisms of antibiotic toxicity in mammals
are not well understood, but may include enzyme or membrane alterations as well as induction of apoptosis (Gerbaux et al. 1996; Van Bambeke et al. 1998; El Mouedden et al. 2000; Sliva and Schnierle, 2007).
Previous studies have demonstrated that in some cases, antibiotics may have antiviral effects (SubakSharpe et al.1969; Macintyre et al. 1991), most likely due to inhibition of host cell functions required
for viral replication. For the present study, several antibiotics were screened for effects on porcine
reproductive and respiratory syndrome virus (PRRSV) in vitro. PRRSV is the etiologic agent of an
economically-important porcine disease (PRRS; Albina et al. 1997; Prieto et al. 2005) and is also a
model for chronic virus infection. The mechanism of chronic PRRSV infection is unclear. The virus
induces several cytokines including interferon-gamma (IFN-γ), which inhibits PRRSV replication in
vitro (Aasted et al. 2002; Cafruny et al. 2006; Johnsen et al. 2002; Rowland et al. 2001). However, the
IFN-γ response in pigs may be delayed or inhibited by unknown factors, and a poorly-neutralizing Th2
Correspondence: William A. Cafruny, Sanford School of Medicine, University of South Dakota, 414 E. Clark St.,
Vermillion, S.D. 57069. Tel: 605-677-6978; Email: bc@actokine.com
Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the
Creative Commons Attribution By licence. For further information go to: http://creativecommons.org/licenses/by/3.0/.

Virology: Research and Treatment 2008:1 17–28

17

Cafruny et al

response may also contribute to virus persistence
(Meier et al. 2003; Meier et al. 2004). PRRSV, and
the related lactate dehydrogenase-elevating virus
(LDV) of mice, are resistant to vaccination strategies, and antivirals for PRRSV are still in an early
stage of development. We show that several quinolone-containing compounds have potent antiPRRSV effects, which correlated with inhibition
of actin expression in MARC-145 cells. Furthermore, quinolone treatment was found to potentiate
the cytokine-mediated inhibition of PRRSV replication in MARC-145 cells and in primary pig
macrophages. These novel drug effects may provide insights into mechanisms of viral replication
as well as the development of future therapeutic
agents for virus infection.

Materials and Methods

macrophages were established in 8-well glass slide
chambers, and inoculated with LDV within 24 h
as described previously (Plagemann and Moennig,
1992; Cafruny et al. 2006).

Viruses and virus infections

MARC-145 cells were infected with the PRRSV
isolate SD-23983, preparing high-titer (~10 6
TCID50 per ml) virus stocks from the culture supernatants of 48–96 h p.i. MARC-145 cells. For the
experiments described, MARC-145 cells were
inoculated with an MOI of about 0.1 TCID50 and
PAMs with an MOI of about 0.5 TCID50 which are
approximately optimal for these systems (Rowland
et al. 2001; Kim et al. 2002; Cafruny et al. 2006).
LDV-P stocks were prepared as previously
described and used to inoculate mouse macrophage
cultures with an MOI of about 1000 (Plagemann
and Moennig, 1992).

Target cells for virus replication

PRRSV was inoculated on monolayer cultures of
a mycoplasma-free MARC-145 cell line (Kim et al.
1993; Meulenberg, 2000) or on primary alveolar
pig macrophages (Oleksiewicz, M.B., Nielsen, J.
1999). The MARC-145 cells were routinely passaged in DMEM containing 10% fetal bovine
serum, and for virus infections the medium was
switched to MEM containing 2% horse serum.
MARC-145 cells for virus infections were grown
for 1–2 days in 8-well glass slide chambers (~30–
40,000 confluent cells/culture; Lab-Tek II; Nalge
Nunc International, as described (Cafruny et al.
2006). Pig cells were collected from 4–8 week old
pigs by lung lavage with PBS (Mengeling et al.
1995; Duan et al. 1997; Oleksiewicz et al. 1999)
and stored at −70 °C. Vials of these cells were
rapidly thawed, centrifuged for 5 min at 1000 × G
to obtain a cell pellet, which was resuspended in
DMEM containing 10% fetal bovine serum. The
cells were then distributed into wells of 8-well slide
chambers, and after about 18 h of incubation at
37 °C, non-adherent cells were removed, and the
adherent cells (primary alveolar porcine macrophages or PAMs) were incubated for an additional
4–6 h prior to PRRSV inoculation. Typically there
were about 10,000–20,000 PAMs per culture well,
with variation noted between experiments but not
within a given experiment, suggesting that the
variation was due to differences among the
collected aliquots of alveolar cells. For LDV
infection, primary mouse (outbred CF1) peritoneal
18

Drugs and drug treatments

Plasmocin™ (product of Cayla, www.cayla.com;
distributed by Invivogen; ant-mpt), nalidixic acid
(Sigma; N5035), ciprofloxacin (Biochemika;
17850), erythromycin (Amresco; 0219-10G),
penicillin (Sigma; P3032) and streptomycin
(Sigma; S9137) were used as sterile preparations
at various concentrations (2.5–250 ug/ml) as indicated in the Results. The recombinant human
antiviral cytokines AK-2 (50 ug/ml) and interferonγ (IFN-γ; 100 ug/ml) were generated by Actokine
Therapeutics and used as previously described
(Cafruny et al. 2006). AK-2 is a cytokine-based
experimental antiviral being developed by Actokine Therapeutics, which consists of recombinant
normal human proteins comprising part of the
mammalian cell response to virus infection (Wong
et al. unpublished; Cafruny et al. 2006).

Fluorescence (FA) detection of virus
replication and actin expression

PRRSV replication was detected using FITClabeled IgG anti-PRRSV nucleocapsid antibodies
(SDOW17; Nelson et al. 1993). MARC-145 cells
or primary alveolar porcine macrophages (PAMs)
were fixed in 80% acetone, and incubated for 1 h
at 37 °C with a 1:100 dilution of FITC-conjugated
SDOW17 antibody made in PBS containing 5%
fetal bovine serum. The fixed PAMS were blocked
with 5% heat-inactivated normal mouse plasma
Virology: Research and Treatment 2008:1
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for 30 min prior to incubation with SDOW17, and
in some experiments incubation of PAMs with
SDOW17 was for 3 h at room temperature. Actin
was stained using 592-phalloidin as described
previously (Cafruny et al. 2006). After incubation
with the fluorescence antibody reagents, the cells
were washed three times with cold PBS prior to
examination by confocal fluorescence microscopy,
using an Olympus BX61 microscope and Fluoview
software. Quantitative analyses were performed
by directly counting fluorescence-positive cells in
experimental and control wells. Multiple experiments were analyzed as shown in the results; the
representative images shown in the figures were
obtained at equivalent PMT settings within each
experiment, and display small scale bars as identified in the figure captions. LDV replication was
determined in primary mouse macrophages as
described previously (Cafruny et al. 1986), counting the total LDV antigen-positive cells per culture
under a fluorescence microscope.

Cytotoxicity testing

The cells used for these experiments exhibited high
(⬎99%; Table 4) viability. Potential cytotoxicity
of the antiviral drugs was assessed by trypan blue
dye-exclusion (Freshney, 1987). After a period of
drug exposure (Table 4), cell cultures were washed
once with PBS and then incubated with 0.4% trypan blue for 5 min at room temperature. Dead cells
were counted under a light microscope and comparison made between drug-treated and untreated
control cultures. The cells were then fixed and
stained with crystal violet, and quantitatively
assessed under the microscope to provide an estimate of total-cell counts under the different culture
conditions. Based on this method, the drug
responses reported here did not correlate with
detectable cytoxicity (see below and Table 4).

Results
Inhibition of PRRSV replication
in MARC-145 cells by quinolonecontaining antibiotics

The first indication that some antibiotics were
capable of inhibiting PRRSV replication emerged
from studies with Plasmocin, a proprietary agent
consisting of quinolone and macrolide antibiotics
which has potent anti-mycoplasma activity.
Virology: Research and Treatment 2008:1

Treament of MARC-145 cells with Plasmocin was
found to inhibit PRRSV replication in a dose- and
time-dependent fashion, as shown in Table 1
A,C,D. Figure 1A illustrates the antiviral effect of
Plasmocin added at the time of virus inoculation,
which almost completely abrogated PRRSV-permissiveness in MARC-145 cells, with a total of
only 20 weakly-PRRSV-positive cells in two
treated cultures, versus a mean of 458 +/− 40
PRRSV-positive cells in control cultures. In contrast, addition of Plasmocin at 3 or 6 h p.i. resulted
in progressively weaker antiviral effects (Fig. 1A
and Table 1).
PRRSV replication in MARC-145 cells was
also inhibited by the quinolones nalidixic acid and
ciprofloxacin (Table 1B and C). The dose- and
time-dependency of the nalidixic acid response are
shown in Table 1B and C. In contrast, neither
erythromycin (a representative macrolide) nor the
combination of penicillin (150 ug/ml) and streptomycin (200 ug/ml) had any significant effect on
PRRSV replication in MARC-145 cells (Table 1E
and F, and Fig. 1C). Combined, these data show
that an early stage of PRRSV replication is inhibited by quinolone antibiotics or quinolonecontaining compounds.
Cytotoxicity testing was carried out by trypan
blue dye exclusion and total cell count analyses.
No cytotoxicity of the antibiotics studied was
observed in MARC-145 cells under our experimental conditions (Table 4). Furthermore, continuous treatment of MARC-145 cells for 2 weeks
with 25 ug/ml Plasmocin had no detectable effect
on cell propagation or viability (Duman et al.
unpublished).Thus, the viral responses appear
unrelated to general cytotoxicity.

Inhibition of PRRSV replication
in primary alveolar porcine
macrophages (PAMs) by plasmocin
and nalidixic acid

Virus responses to Plasmocin and nalidixic acid
were similar in primary alveolar porcine macrophages (PAMs) from several different pigs to those
seen in MARC-145 cells (Table 2). While there
were some variations in the magnitudes of the
antiviral responses, both Plasmocin and nalidixic
acid were potent antivirals in cultured PAMs,
whereas an antiviral effect of erythromycin was
not noted. The source of the variation we observed
is not known, but could be due to differences
19
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Table 1. Antibiotic-mediated inhibition of PRRSV replication in MARC-145 cells.
Expt. Drug treatment1

Percent of PRRSVpositive
cells relative to control

A. Plasmocin dose response (drug at T = 0 h p.i.)
Plasmocin 250 ug/ml
Plasmocin 25 ug/ml
Plasmocin 2.5 ug/ml
B. Nalidixic acid dose response (drug at T = 0 h p.i.)
Nalidixic acid 125 ug/ml
Nalidixic acid 25 ug/ml
Nalidixic acid 12.5 ug/ml
C. PRRSV inhibition by time of addition
Plasmocin 125 ug/ml T = 0 h p.i.
Plasmocin 125 ug/ml T = 5 h p.i.
Nalidixic acid 125 ug/ml T = 0 h p.i.
Nalidixic acid 125 ug/ml T = 5 h p.i.
Ciprofloxacin 125 ug/ml T = 0 h p.i.
Ciprofloxacin 125 ug/ml T = 5 h p.i.
D. PRRSV inhibition reduced by post-treatment
Plasmocin 125 ug/ml T = 0 h p.i.
Plasmocin 125 ug/ml T = 3 h p.i.
Plasmocin 125 ug/ml T = 6 h p.i.
E. Weak or no PRRSV inhibition by erythromycin (mean of 2 expts.)
Erythromycin 250 ug/ml
Erythromycin 125 ug/ml
Erythromycin 62 ug/ml
Erythromycin 31 ug/ml
F. Penicillin/streptomycin: no effect on PRRSV replication
Pen 150 ug/ml and strep 200 ug/ml
Pen 150 ug/ml and strep 200 ug/ml
Pen 150 ug/ml and strep 200 ug/ml
Pen 150 ug/ml and strep 200 ug/ml

0
53
73
0
64
103
11
72
1
6
18
61
2
13
66
85
110
125
104
94
114
99
92

1
Drug dose and time of addition are indicated; for C, drugs were added at the time of virus inoculation (T = 0 h p.i.) or at 5 h p.i. (T = 5 h p.i.).
Percent results are derived from means of duplicate wells, with ⬍20% variation between well counts. For A-D, dose- and time-dependent
antiviral effects of the antibiotics were apparent, and only the 12.5 ug/ml dose of nalidixic acid failed to show at least some antiviral activity.

between pigs or among vials of cells obtained from
the same pig. Cytotoxicity studies demonstrated
occasional reduction in total cell numbers and/or
enhanced uptake of trypan blue at the highest
Plasmocin concentration (250 ug/ml), but neither
nalidixic acid nor Plasmocin at lower but effective
concentrations appeared to be cytotoxic to PAMs
by these methods (Table 4). Figure 1B illustrates
the antiviral effect of 25 ug/ml Plasmocin in PAMs.
Additional PAM responses to antibiotics are
described below.

Correlation of quinolone-mediated
inhibition of PRRSV replication
with reduced actin expression

Previous studies showed that PRRSV replication
is dependent on an intact cytoskeletion and
20

is inhibited by the actin-disrupting agent
cytochalasin D (Cafruny et al. 2006). As illustrated
in Figure 1D, actin expression was reduced in
cultured MARC-145 cells by both Plasmocin and
nalidixic acid, but little effect of erythromycin on
actin expression was observed. Inhibition of actin
expression by Plasmocin and nalidixic acid was
dose-dependent (data not shown).

Potentiation of cytokine-mediated
inhibition of PRRSV replication
by nalidixic acid

AK-2 and IFN-γ are potent inhibitors of LDV and
PRRSV replication, establishing an antiviral state
in MARC-145 cells, as well as primary pig and
mouse macrophages (Cafruny et al. 2006). For the
present study, sub-optimal concentrations (below
Virology: Research and Treatment 2008:1
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the concentrations with maximum antiviral activity
(Cafruny et al. 2006, and Tables 1 and 2) of these
cytokines as well as nalidixic acid (25 ug/ml)
were used to treat cultured MARC-145 cells or
primary alveolar pig macrophages (PAMs) just
prior to or at the time of PRRSV inoculation. In
most experiments, the drugs were used for 5 h
pretreatment only, and after drug-removal, the cells
were inoculated with PRRSV, fixed at about 14 h

p.i, and stained for PRRSV antigen expression.
Suboptimal concentrations of nalidixic acid, in
some cases below the threshold of detectable
antiviral effect by pretreatment, were found to
synergize with low levels of AK-2 or IFN-γ, to
inhibit PRRSV replication, as shown in Table 3.
In experiment #1, the combined drug effect
appeared to be additive, but in most of the
experiments actual potentiation was observed since

A. Time course of MARC-145 cell response to 125 ug/ml Plasmocin
Control (458 +/−40)

Drug at T = 3 h p.i. (58 +/−2)

Drug at T = 0 h p.i. (10 +/−3)

Drug at T = 6 h p.i. (302 +/−37)

B. Inhibition of PRRSV replication in primary pig macrophages
Control

Virology: Research and Treatment 2008:1

Plasmocin 25 ug/ml

21

Cafruny et al

C. No effect of penicillin or streptomycin on PRRSV replication
No antibiotics

Penicillin & streptomycin

D. PRRSV inhibition correlates with inhibition of actin expression
Control (pen/strep)

Nalidixic acid 250 ug/ml

Plasmocin 250 ug/ml

Erythromycin 250 ug/ml

Figure 1. Inhibition of PRRSV replication in cultured MARC-145 cells and in primary alveolar porcine macrophages (PAMs) by Plasmocin, and correlation of the quinolone antiviral effect with inhibition of actin expression in MARC-145 cells.
A. Time course of the antiviral response to 125 ug/ml Plasmocin (numbers in parentheses are mean +/− SD PRRSV-positive cells/culture).
B. Inhibition of PRRSV replication in PAMs by 25 ug/ml Plasmocin. C. No effect of penicillin and streptomycin on PRRSV replication in MARC145 cells. D. Antiviral effects of Plasmocin and nalidixic acid correlate with inhibition of actin expression in MARC-145 cells. Scale bars =
100 um (A); 20 um (B); 100 um (C); 50 um (D).

the nalidixic acid concentration was below an
effective threshold. The drug effects were not due
to detectable cytotoxicity (Table 4) or loss of total
cells due to drug exposure. Figure 2A illustrates
these viral responses to sub-optimal quinolone and
22

cytokine concentrations, and Figure 2B illustrates
partial (reduced intensity and scope of PRRSV
antigen) antiviral responses which were observed
in some cells due to combination drug treatment
at sub-optimal concentrations.
Virology: Research and Treatment 2008:1
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Table 2. Drug responses of primary alveolar porcine macrophages.
Drug treatment1
Plasmocin

Nalidixic acid

Erythromycin

250 ug/ml
25 ug/ml
125 ug/ml
125 ug/ml
125 ug/ml
125 ug/ml
50 ug/ml
25 ug/ml
250 ug/ml
250 ug/ml
250 ug/ml
250 ug/ml
250 ug/ml
125 ug/ml
250 ug/ml
125 ug/ml
62 ug/ml

Expt.

Percent PRRSV-positive cells relative to control

1
2
3
4
5
6
6
6
1
2
3
4
5
1
2
2
2

0
0
28
38
0
9
80
76
21
18
20
0
13
122
98
104
106

1

PAMs were treated with the indicated drug doses, testing responses in individual cultures against matched control (no drug) cultures for
each experiment.

Table 3. Potentiation of cytokine-mediated inhibition of PRRSV replication by nalidixic acid: drug synergy with
sub-optimal drug concentrations.
Expt. cells

Treatment/Pretreatment1

PRRSV response2

1. PAMs
(Treatment)

Nalidixic acid (25 ug/ml)
AK-2 (125 ng/ml)
AK-2 + Nalidixic acid
Nalidixic acid (25 ug/ml)
AK-2 (125 ng/ml)
AK-2 + Nalidixic acid
Nalidixic acid (25 ug/ml)
IFN-γ (400 ng/ml)
IFN-γ + Nalidixic acid
Control
Nalidixic acid (25 ug/ml)
AK-2 (62 ng/ml)
AK-2 + Nalidixic acid
Control
Nalidixic acid (25 ug/ml)
AK-2 (31 ng/ml)
AK-2 + Nalidixic acid
Control
Nalidixic acid (25 ug/ml)
IFN-γ (400 ng/ml)
IFN-γ + Nalidixic acid
Control
Nalidixic acid (25 ug/ml)
IFN-γ (200 ng/ml)
IFN-γ + Nalidixic acid
Control
Nalidixic acid (25 ug/ml)
IFN-γ (400 ng/ml)
IFN-γ + Nalidixic acid

81% of control
74% of control
45% of control
107% of control
145% of control
20% of control
114% of control
103% of control
31% of control
251 +/− 27 positive cells
221 +/− 20 positive cells
38 +/− 6 positive cells
10 +/− 4 positive cells
363 +/− 30 positive cells
543 +/− 44 positive cells
166 +/− 42 positive cells
104 +/− 14 positive cells
136 +/− 22 positive cells
164 +/− 55 positive cells
68 +/− 1 positive cells
40 +/− 10 positive cells
514 +/− 17 positive cells
570 +/− 33 positive cells
587 +/− 32 positive cells
479 +/− 26 positive cells
192 +/− 2 positive cells
188 +/− 33 positive cells
114 +/− 4 positive cells
75 +/− 2 positive cells

2. PAMs
(Pretreatment)
3. PAMs
(Pretreatment)
4. MARC-145
(Pretreatment)
5. MARC-145
(Pretreatment)
6. MARC-145
(Pretreatment)
7. MARC-145
(Pretreatment)
8. MARC-145
(Pretreatment)

1
Pretreatment consisted of 5 h incubation followed by removal of drugs and inoculation with PRRSV. For the treatment protocol, drugs
were present throughout the virus exposure phase as well as during a one-h pretreatment period.
2
PAM responses are reported as the percent infection relative to control cultures; MARC-145 cell responses are reported as mean total
PRRSV-positive cells/culture +/− SD for duplicate wells.

Virology: Research and Treatment 2008:1
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Table 4. Cytotoxicity testing by trypan blue dye exclusion.
Expt.

Cells

Drug treatment

No. or % dead cells/well*

1

PAM

2

PAM

3

PAM

4

PAM

5

PAM

6

PAM

7

MARC-145

8

MARC-145

9

MARC-145

10

MARC-145

11

MARC-145

None
Plasmocin 250 ug/ml
50 ug/ml
25 ug/ml
None
Plasmocin 250 ug/ml
125 ug/ml
25 ug/ml
None (Control)
IFN-γ 400 ng/ml
Nalidixic acid 25 ug/ml
IFN-γ + Nalidixic acid
None (Control)
AK-2 125 ng/ml
NA 25 ug/ml
AK-2 + Nalidixic acid
None
Plasmocin 25 ug/ml
Nalidixic acid 250 ug/ml
None
Plasmocin 25 ug/ml
Nalidixic acid 250 ug/ml
None (Control)
AK-2 125 ug/ml
Nalidixic acid 25 ug/ml
AK-2 + Nalidixic acid
None (Control)
Plasmocin 250 ug/ml
25 ug/ml
2.5 ug/ml
None (Control)
Plasmocin 250 ug/ml
25 ug/ml
2.5 ug/ml
None (Control)
Plasmocin 250 ug/ml
125 ug/ml
50 ug/ml
None (Control)
Nalidixic acid 250 ng/ml
125 ng/ml
62 ng/ml

⬍1%
∼50%
⬍1%
⬍1%
37
∼20%
12
10
6
3
2
2
5
3
2
3
2
1
2
27
19
31
34 +/− 9
16 +/− 6
12 +/− 6
16 +/− 2
4 +/− 6
4 +/− 1
2 +/− 1
1 +/−1
1 +/− 1
1 +/− 1
2 +/−1
2 +/− 1
8 +/− 4
8 +/− 1
5 +/− 2
6 +/− 4
11 +/− 4
9 +/− 4
18 +/− 4
11 +/− 8

*Dead cells were stained with trypan blue at about 22−24 h post-drug treatment for all experiments except #8 and #9, which were stained
at 6 h post-drug treatment. For expts. #1 (all cultures) and 2 (Plasmocin 250 ug/ml), the% dead cells is given; for expt. #2 (control and lower
Plasmocin doses) and all other experiments, the total dead cells per culture well are shown. MARC-145 cell results are mean +/− SD for
duplicate wells. Field counts were assessed for all wells after crystal violet staining and no detectable differences were observed between
drug-treated and control wells except for expts. #1 and 2, in which there was about 50% reduction in total PAMs at the highest concentration
only (250 ug/ml) of plasmocin. Concentrations of drugs in combination were the same as when used individually within each experiment.

Inhibition of lactate
dehydrogenase-elevation virus (LDV)
replication by plasmocin

Primary peritoneal macrophages were LDV
infected with or without Plasmocin in the culture
medium. At 8 h p.i. the cells were fixed and stained
24

for LDV antigen. Plasmocin at 250 ug/ml
completely inhibited LDV replication (no positive
cells per well), and at 25 ug partially inhibited LDV
replication (179 +/− 22 LDV-positive cells per
well, versus 272 +/− 16 positive cells per well in
the untreated control, mean +/− SD given for
duplicate wells.
Virology: Research and Treatment 2008:1
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A. Nalidixic acid synergy with AK-2
Control

AK-2 + Nalidixic acid

Nalidixic acid only

AK-2 only

B. Partial PRRSV resistance in some cells after combined drug treatment at
sub-optimal concentrations
AK-2 only

Nalidixic acid only

AK-2 + Nalidixic acid

Figure 2. Potentiation of the antiviral cytokine response by nalidixic acid.
A. Sub-optimal concentrations of nalidixic acid (25 ug/ml) and AK-2 (31 ng/ml) were used to reveal drug synergy. B. Partial resistance (arrows)
in some cells after combined sub-optimal dosing with nalidixic acid and AK-2. Single-drug treatment results are shown for comparison. Scale
bars = 50 um.

Virology: Research and Treatment 2008:1
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Discussion

These results demonstrate the ability of several
quinolone-containing antibiotics to inhibit arterivirus replication. Antibiotic-mediated suppression
of both PRRSV and LDV was observed, the former
in both primary pig cells and the MARC-145 cell
line, and the latter in primary mouse macrophages.
Thus, the antiviral effects of certain quinolone
antibiotics are expressed in at least three different
cell types. The PRRSV responses were shown to
be dose- and time-dependent, and selectivity of the
quinolone effects was also observed.
Nalidixic acid is the prototype quinolone
(Crump et al. 2003) and was investigated further,
in combination with the antiviral cytokines AK-2
and IFN-γ, employing pretreatment with suboptimal drug doses to search for antiviral synergy.
In both MARC-145 cells and primary pig macrophages, nalidixic acid was found to potentiate the
antiviral effects of AK-2 and IFN-γ, even when
single-drug exposures under these conditions failed
to inhibit viral permissiveness. The mechanism is
not clear, but potentiation under conditions in
which the nalidixic acid concentration used failed
to inhibit virus suggest the possibility of drug
synergy, in which the combined activity is greater
than the sum of individual activities (Wingard et al.
1991). In addition, exposure to the drug combinations induced partial resistance to virus replication
in some cells.
Quinolones inhibit bacterial growth by interfering with the replication fork (acting on DNA
gyrases and topoisomerases). The mechanism by
which quinolones mediate antiviral effects in mammalian cells is not known from the present work,
but does not appear to be related to direct cellular
cytotoxicity, since dye-exclusion and cell count
studies failed to support a detectable cytotoxic
effect at the drug concentrations used. Furthermore,
post-treatment by 3–6 h relative to virus inoculation was less effective than simultaneous treatment,
indicating that an early stage in virus infection was
the target rather than a general cytotoxicity in the
cultured cells.
AK-2 and IFN-γ exert their antiviral effects
by activating an antiviral gene program, consistent with the antiviral efficacy of these drugs
during pretreatment followed by drug wash-out
in our studies. Synergy (defined by combined
activity greater than the sum of independent
activities; Wingard et al. 1991) of nalidixic acid
in combination with AK-2 or IFN-γ during our
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pretreatment strategies, suggests that this quinolone may also target viral permissiveness. Additional studies would be of interest to discriminate
between the possibilities of a metabolic toxicity
with antiviral side-effects and a more conventional activation of viral resistance by combination drug treatment.
The arteriviruses PRRSV and LDV are both
dependent on an intact cytoskeleton for replication,
and actin expression appears to be required for
PRRSV replication, since inhibition of actin by
cytochalasin D impairs the ability of PRRSV to infect
cultured target cells (Cafruny et al. 2006). The present study demonstrated a correlation between actin
and virus inhibition by the quinolone-containing
antibiotics, although exposure to penicillin,
streptomycin, or erythromycin failed to inhibit virus
or actin expression. The cytoskeleton is a potentially
important target in the identification of new antiviral
molecules (Dohner and Sodeik, 2005); while it is
intriguing to speculate that actin may be involved in
the antiviral mechanisms of these quinolones, further
studies are needed to address this possibility.
Previous studies have shown that the aminoglycoside hygromycin B inhibits mouse hepatitis virus
(Macintyre et al. 1991), the macrolide bafilomycin
inhibits African swine fever virus in porcine macrophages due to inhibition of the endosomal/lysosomal pump (Natale and McCullough, 1998), and
rifampin inhibits poxviruses via effects on the viral
envelope and protein assembly (Subak-Sharpe
et al. 1969; Zhang and Moss, 1992; Sodeik et al.
1994). Coumermycin, like the quinolones an
inhibitor of bacterial DNA gyrase, also inhibits
retrovirus replication (Varnier et al. 1984). Thus,
the present results add to the evidence that antibiotics may have antiviral activity, and furthermore
demonstrate the ability of an antibiotic to potentiate antiviral cytokine effects, providing a new
avenue for the study of antiviral mechanisms.
These results also have implications for antiviral
treatment or prevention strategies, utilizing combination therapy with the benefit of lowered toxicity, and particularly in vivo where the internal
cytokine environment may help trigger antiviral
responses to sub-optimal quinolone levels. While
additional studies would be needed to determine
clinical relevance, lipid-soluble antibiotics become
concentrated in alveolar macrophages (Hand et al.
1984; Hand and King-Thompson, 1989), and ciprofloxacin levels of about 35 ug/ml have been
reported in alveolar macrophages after oral dosing
Virology: Research and Treatment 2008:1
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of humans (Gotfried et al. 2001), suggesting the
potential for in vivo activity of quinolone derivatives against alveolar macrophage-tropic viruses
such as PRRSV.
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